跳至主要内容
临床试验/LBCTR2022035014
LBCTR2022035014招募中不适用

Real-World Evidence Study on AbeMaciclib Treatment Patterns and Effectiveness in Patients with HR+/HER2- Locally Advanced or Metastatic BReAst CancEr in Kuwait and Lebanon.

Eli Lilly0 个研究点目标入组 100 人开始时间: 2022年12月9日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
Eli Lilly
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 90(—)
性别
Female

入选标准

  • Inclusion criteria
  • Patients eligible for inclusion in this study have to fulfill all of the following criteria:
  • 1. Adult breast cancer female patients =18 years old at the start of receiving Abemaciclib,
  • whether as a single-agent treatment or combination treatment
  • 2. Premenopausal or postmenopausal patients with histologically proven HR-positive,
  • HER2-negative with locally advanced or metastatic breast cancer (De-novo or
  • recurrence/progression of early breast cancer)
  • 3. Patients who are being treated or have been treated with Abemaciclib (VERZENIO™),
  • whether as a single-agent treatment or combination treatment, for at least three months
  • before data collection
  • 4. Patients treated with Abemaciclib (VERZENIO™), whether as a single-agent treatment
  • or combination treatment, according to the SmPC.

排除标准

  • Exclusion criteria
  • 1. Patients previously included in Abemaciclib clinical trial
  • 2. Patients with evidence of other prior second primary concurrent malignancy apart from
  • locally advanced or metastatic breast cancer.

研究者

发起方
Eli Lilly

相似试验

已完成
不适用
The Real-World Data of Treatment with Abemaciclib for HR-positive HER2-negative Metastatic Breast Cancer: A Multicentral Cohort StudyHR-positive HER2-negative Metastatic Breast Cancer
JPRN-UMIN000043149Aichi Cancer Center200
已完成
不适用
ested Case Control Study of Abemaciclib-induced Interstitial Lung DiseaseBreast cancer
JPRN-UMIN000040357SHOWA University Advanced Cancer Treatment Laboratory2,000
进行中(未招募)
1 期
A Phase 1b/2 Study of Abemaciclib Plus Chemotherapy and/or Chemoimmunotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Solid TumorsPediatric and Young Adult Patients Relapsed/Refractory Solid TumorsMedDRA version: 20.0Level: PTClassification code 10015560Term: Ewing's sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10073335Term: Rhabdoid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10039022Term: RhabdomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10031291Term: OsteosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10080666Term: Diffuse intrinsic pontine gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10065443Term: Malignant gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10027107Term: MedulloblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10014967Term: EpendymomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065252
EUCTR2019-002931-27-BEEli Lilly and Company60
进行中(未招募)
1 期
A Phase 1b/2 Study of Abemaciclib Plus Chemotherapy and/or Chemoimmunotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory SolidTumorsPediatric and Young Adult Patients Relapsed/Refractory Solid TumorsMedDRA version: 20.0Level: PTClassification code 10015560Term: Ewing's sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10073335Term: Rhabdoid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10039022Term: RhabdomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10031291Term: OsteosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10080666Term: Diffuse intrinsic pontine gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10065443Term: Malignant gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10027107Term: MedulloblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10014967Term: EpendymomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065252
EUCTR2019-002931-27-DEEli Lilly and Company60
进行中(未招募)
1 期
A trial comparing a drug named Abemaciclib and another drug named Docetaxel in patients with lung cancer who have already received chemotherapy treatements.Stage IV squamous NSCLC patients who have progressed after platinum-based chemotherapyMedDRA version: 20.0Level: PTClassification code 10025125Term: Lung squamous cell carcinoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-004832-20-PLEli Lilly and Company150